Sequist, Lecia

Institution/Organization
Massachusetts General Hospital

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
Understood

Disclosure of Potential Conflicts
Understood

COI Disclosure

Disclosures
AstraZeneca: Consulting
AstraZeneca: Clinical trial funding; Up to 2021
Genentech: Data Safety Monitoring Committee; Up to 2021
Massachusetts General Hospital: Primary site of Employment
American Lung Association: Educational lecture; 2020
American Society of Clinical Oncology: Educational lecture; 2019
BioAscend: Educational lecture; 2020
Clinical Care Options: Educational lecture; 2021
Creative Educational Concepts: Lecture and course director Personal; Up to 2021
Dana Farber Cancer Institute: Lecture; 2019
E-vate LTD: Consulting; 2020
Flagship Labs 67, Inc: consulting; 2020
Harvard University: Educational lecture; 2019
Inception Digital: Educational lecture; 2019
Intellisphere, LLC: Educational lecture; 2019
Janssen: Educational lecture; 2020
National Cancer Institute: Steering Committee; Up to 2021
LUNGevity: Scientific Advisory Board; Up to 2021
MJH Healthcare Holdings, LLC: Educational Lecture; Up to 2021
Nexus Global Group Science, LLC: Consulting; 2019
Ohio State University: Educational Lecture; 2021
Peer View, LLC: Educational Lecture; 2021
PlatformQ Health, Inc: Consulting; 2019
Prime Oncology: Educational lecture; 2019
PSL Group Americas: Educational Lecture; 2019
Research To Practice: Educational Lecture; Up to 2021
Touch Medical Media: Educational Lecture; 2021
Triptych Health Partners: Educational Lecture; 2021
UpToDate: Writing; Up to 2021
WebMD: Educational lectures and course director; up to 2021
Novartis: Clinical Trial
Delfi: Clinical Trial

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agreed

**Standards of Conduct Agreement**

Agreed

**IASLC's Tax-Exempt Status**

Agreed

**COI Follow-Up**

Disclose any clinical trials you are conducting for institution fees.

I serve as the PI for the following clinical trials at my institution (2019-2021):
1. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGFRm, Metastatic NSCLC who have Progressed Extracranially following First-Line Osimertinib Therapy (COMPEL), funded by AstraZeneca

2. A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients with Advanced/Metastatic EGFR T790M Mutation-Positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy, funded by AstraZeneca

3. A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a standard of care epidermal growth factor receptor Tyrosine Kinase Inhibitor as First-Line treatment in patients with epidermal growth factor receptor mutation positive, locally advanced or metastatic non-small cell lung cancer, funded by AstraZeneca

4. A Multi-arm, Phase Ib, Open-Label, Multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9291 in combination with ascending doses of novel therapeutics in patients with EGFRm+ advanced NSCLC who has progressed following therapy with an EGFR TKI (TATTON), funded by AstraZeneca

5. A Phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer, funded by Novartis

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

1. LUNGevity, Scientific Advisory Board
2. American Lung Association, Massachusetts Leadership Board, Scientific and Medical Editorial Review Panel, and Chair of the local Lung Force Expo meeting
3. Member, Board of Directors, Upstage Lung Cancer Foundation
4. Oregon Health Sciences University Cancer Early Detection and Advanced Research Center, External Advisory Committee
5. Leader, Cancer Risk, Prevention, and Early Detection Program, Dana-Farber Harvard Cancer Center
6. The Fleischner Study, Member-Elect
7. NCI Thoracic Malignancy Steering Committee, member


9. The Oncology Journal: Lung cancer section editor

10. Eastern Cooperative Oncology Group: lung cancer core committee

11. American Association for Cancer Research: Lung Cancer Research Grants Scientific Review Committee, Chair, Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Selection Committee

12. European Society of Medical Oncology, Contributor, EGFR mutation positive lung cancer consensus guidelines and member, Scientific Committee

13. American Cancer Society, PI for a grant which gives out institutional research grants


Have you received any personal fees from any outside accreditation entities such as CME companies?

Yes, they are all disclosed above

Are you conducting clinical trials with any oncology equipment companies?

Yes

Please disclose the names of any oncology equipment companies for which you are conducting any clinical trials.

Will be opening a clinical trial soon with a blood test made by Delfi Diagnostics